Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity (Q38108353)

29 August 2017

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity (English)

1 reference

29 August 2017

1 reference

Alan G Ramsay

1

1 reference

PubMed ID

23691926

29 August 2017

language of work or name

English

0 references

publication date

21 May 2013

1 reference

British Journal of Haematology

29 August 2017

1 reference

29 August 2017

162

1 reference

29 August 2017

3

1 reference

29 August 2017

313-325

1 reference

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

29 August 2017

1 reference

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

21 January 2018

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

21 January 2018

1 reference

Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside

21 January 2018

1 reference

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials

21 January 2018

1 reference

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

21 January 2018

1 reference

A restricted cell population propagates glioblastoma growth after chemotherapy

21 January 2018

1 reference

Janus kinase deregulation in leukemia and lymphoma

21 January 2018

1 reference

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

21 January 2018

1 reference

Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.

21 January 2018

1 reference

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

21 January 2018

1 reference

Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

How I treat plasma cell leukemia

21 January 2018

1 reference

New insights into the T cell synapse from single molecule techniques

21 January 2018

1 reference

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

21 January 2018

1 reference

The role of B7 family molecules in hematologic malignancy

21 January 2018

1 reference

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia

21 January 2018

1 reference

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Cancer stem cells, CD200 and immunoevasion

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.

21 January 2018

1 reference

Pathogenesis of follicular lymphoma

21 January 2018

1 reference

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

21 January 2018

1 reference

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.

21 January 2018

1 reference

Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells

21 January 2018

1 reference

Lenalidomide enhances anti-myeloma cellular immunity

21 January 2018

1 reference

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

21 January 2018

1 reference

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

21 January 2018

1 reference

Cancer immunotherapy comes of age

21 January 2018

1 reference

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

21 January 2018

1 reference

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

21 January 2018

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention

21 January 2018

1 reference

Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

21 January 2018

1 reference

Immunology beats cancer: a blueprint for successful translation

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Immunotherapy earns its spot in the ranks of cancer therapy

21 January 2018

1 reference

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

Putting the brakes on BTLA in T cell-mediated cancer immunotherapy

21 January 2018

1 reference

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

BCR-ABL kinase is dead; long live the CML stem cell

21 January 2018

1 reference

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

21 January 2018

1 reference

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

21 January 2018

1 reference

Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide

21 January 2018

1 reference

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

T-cell function in chronic lymphocytic leukaemia

21 January 2018

1 reference

Chronic lymphocytic leukemia: an update on biology and treatment.

21 January 2018

1 reference

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.

21 January 2018

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.

21 January 2018

1 reference

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

21 January 2018

1 reference

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

21 January 2018

1 reference

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells

21 January 2018

1 reference

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

21 January 2018

1 reference

21 January 2018

1 reference

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

21 January 2018

1 reference

The B7 homologues and their receptors in hematologic malignancies.

21 January 2018

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

The role of CD200 in immunity to B cell lymphoma

21 January 2018

1 reference

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

Fine tuning the immune response through B7-H3 and B7-H4

21 January 2018

1 reference

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

21 January 2018

1 reference

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

21 January 2018

1 reference

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12380

1 reference

29 August 2017

1 reference

PubMed ID

23691926